Dr. Hull, Lead Pharmacologist within FDA’s Center for Tobacco Products, joined the Center in 2014 from NIH’s National Cancer Institute. Her research interests include the behavioral and clinical pharmacology aspects of tobacco product use and the impact use patterns have on addiction and dependence. Dr. Hull is responsible for the design, implementation, and oversight of contractual clinical and preclinical studies related to evaluating the abuse liability of tobacco products, as well as reviewing tobacco product regulatory submissions.

She is also FDA’s Behavioral and Clinical Pharmacology Representative on the Population Assessment of Tobacco and Health (PATH) Study, a national longitudinal study of tobacco use and how it affects the health of people in the United States. She received her Ph.D. in Pharmacology and Toxicology from Virginia Commonwealth University in 2009.